Thermo Fisher Scientific Launches Comprehensive SLE Registry to Address Critical Research Gaps
核心洞察
Thermo Fisher Scientific (搜索) has launched the CorEvitas (搜索) Systemic Lupus Erythematosus (搜索) (SLE (搜索)) Registry, a multi-center prospective database collecting real-world data on this complex autoimmune disease affecting multiple organ systems.
The registry will collect longitudinal clinical data across multiple domains including drug utilization, quality of life, disease activity, and adverse events, addressing a critical need for robust data as new therapies emerge.
Complemented by a biorepository collecting blood specimens linked to clinical data, the registry aims to support drug discovery, biomarker development, and regulatory-grade safety studies for this predominantly female-affecting condition.
Thermo Fisher Scientific (搜索) announced the launch of the CorEvitas (搜索) Systemic Lupus Erythematosus (搜索) (SLE (搜索)) Registry, addressing a significant gap in real-world data collection for this complex autoimmune disease. The multi-center, prospective registry will leverage the company's established rheumatology physician network to gather comprehensive clinical information about SLE, a condition in which the immune system attacks healthy tissues, potentially damaging skin, joints, blood, and vital organs.
The registry represents the 13th independent CorEvitas (搜索) registry and will focus on North American patients, significant as the United States has the second-highest incidence of SLE (搜索) globally. It aims to provide critical insights into treatment effectiveness and safety profiles as new therapies enter the market.
Understanding the Disease Burden
SLE (搜索), the most common form of lupus (搜索), presents with symptoms ranging from mild to life-threatening. Patients typically experience extreme fatigue, joint and muscle pain, headaches, fever, hair loss, and photosensitivity. The disease disproportionately affects women, with approximately 90% of SLE patients being female.
The condition's etiology remains unclear, though researchers believe environmental, genetic, and hormonal factors contribute to its development. SLE (搜索)'s manifestation varies significantly between patients and fluctuates over time, creating substantial challenges for diagnosis and treatment.
Dr. Jeffrey Greenberg, Chief Medical Officer at CorEvitas (搜索), emphasized the registry's importance: "This independent, multi-drug registry and linked biorepository fill a critical gap for our clients and the broader research community, particularly as newer therapies and treatment paradigms are prescribed. High-quality, real-world data can drive much-needed insights on novel treatments and provide hope for patients suffering from this chronic illness."
Comprehensive Data Collection Framework
The registry will collect longitudinal clinical data from both enrolled patients and their treating rheumatologists across multiple health outcome domains. These include:
- Drug utilization patterns
- Quality of life measurements
- Disease activity and severity indicators
- Medical comorbidities
- Diagnostic test results
- Adverse events
This structured approach will create a regulatory-grade dataset spanning more than 500 investigator sites, adding to CorEvitas (搜索)' existing database of over 100,000 patients followed longitudinally across various autoimmune and inflammatory conditions.
Biorepository Component Enhances Research Value
Complementing the clinical registry, Thermo Fisher has established a CorEvitas (搜索) SLE (搜索) biorepository that will collect blood specimens linked to clinical data from enrolled registry patients. This biological sample collection will support additional research applications, including:
- Drug discovery and development initiatives
- Biomarker identification for disease progression prediction
- Indicators of drug response
The registry was launched with scientific guidance from prominent lupus (搜索) researchers Dr. Anca Askanase, Professor of Medicine at Columbia University Medical Center, and Dr. George Tsokos, Professor of Medicine at Harvard Medical School.
Addressing Treatment Evolution
The timing of this registry is particularly significant as the SLE (搜索) treatment landscape evolves. While only a small number of biologics (搜索) have been approved for SLE treatment to date, an array of targeted and cellular therapies are currently in development. The registry will provide crucial real-world evidence to evaluate these emerging treatments.
The CorEvitas (搜索) independent registry model has already gained acceptance from regulators for long-term post-authorization safety studies across various disease indications, positioning this new SLE (搜索) registry as a valuable resource for regulatory decision-making.
For pharmaceutical researchers and clinicians interested in accessing this resource, Thermo Fisher is accepting information requests at sle (搜索)@corevitas (搜索).com.